Psilocybin-Assisted Therapy for Cocaine Addiction: New Study

For decades, cocaine addiction has remained one of the most difficult substance use disorders to treat. While many people can stop temporarily, long-term relapse rates remain high, and unlike opioid use disorder, there are still no FDA-approved medications specifically designed to treat cocaine addiction. Now, researchers are exploring whether psychedelic compounds found in certain mushrooms could offer a new path forward.

A groundbreaking study¹ published in JAMA Network Open is drawing national attention after researchers found that psilocybin-assisted therapy significantly reduced cocaine use among participants with cocaine use disorder. The findings are adding to a growing body of research suggesting psychedelics may have therapeutic potential for addiction, mental health disorders, and behavioral change. Let’s dive into the study and what it means for the future of addiction treatment.

What Is Psilocybin?

Psilocybin is the naturally occurring psychedelic compound found in certain species of mushrooms, often referred to as “magic mushrooms.” Once consumed, psilocybin converts into psilocin in the body, which interacts with serotonin receptors in the brain, particularly the 5-HT2A receptor.

Researchers believe this interaction may temporarily increase neuroplasticity, disrupt rigid thought patterns, and create opportunities for deep emotional and psychological reflection. In therapeutic settings, psilocybin is typically combined with structured psychotherapy rather than used as a standalone treatment.

Over the past several years, psilocybin research has expanded rapidly. Studies have explored its potential role in treating depression, PTSD, anxiety, alcohol use disorder, nicotine dependence, and now cocaine addiction.

Why Cocaine Use Disorder Is So Difficult to Treat

Cocaine use disorder is a serious public health issue that affects millions of people worldwide. Cocaine stimulates the brain’s reward system by dramatically increasing dopamine levels, producing intense feelings of energy, confidence, and euphoria. However, repeated use can fundamentally alter brain chemistry and behavior over time.

Many people living with cocaine addiction experience:

• Strong cravings
• Cycles of relapse and abstinence
• Anxiety and depression
• Sleep disruption
• Financial and social instability
• Increased risk of cardiovascular problems

One of the biggest challenges is that there are currently no proven pharmaceutical treatments specifically approved for cocaine use disorder. Most treatment programs rely heavily on behavioral therapies, counseling, peer support, and relapse prevention strategies. Recently, researchers have become increasingly interested in novel therapeutic approaches like psychedelic-assisted therapy. This shift mirrors the broader evolution in addiction medicine, where patients and providers, frustrated by the limitations of conventional pharmaceuticals, are increasingly looking toward natural compounds—similar to the rise of medical cannabis—as viable, evidence-backed tools for harm reduction and symptom management.

Inside the Psilocybin Cocaine Addiction Study

The clinical trial, published online in May 2026, evaluated whether psilocybin combined with psychotherapy could help people reduce or stop cocaine use.

Researchers conducted a randomized, quadruple-blind, placebo-controlled clinical trial involving 40 adults diagnosed with cocaine use disorder. Participants were motivated to quit cocaine and were recruited between 2015 and 2023 at a major medical research center in the United States. The study population represented many individuals often underrepresented in clinical research. Most participants were Black men from lower socioeconomic backgrounds, with many reporting annual incomes of $20,000 or less.

Participants were randomly assigned to receive either:

• A single oral dose of psilocybin (25 mg per 70 kg of body weight)
• An active placebo containing diphenhydramine

Both groups also underwent structured psychotherapy that included cognitive behavioral treatment before and after the dosing session. Therapy occurred for approximately one month leading up to treatment and another month afterward. This is an important detail because researchers increasingly emphasize that psychedelic therapy is not simply about taking a substance. The therapeutic environment, preparation, guidance, and integration afterward may play a major role in outcomes.

The Results: Psychedelics for Cocaine Addiction

The study found that participants who received psilocybin experienced substantially better outcomes than those who received the placebo. The psilocybin group had:

• A significantly higher percentage of cocaine-abstinent days
• A greater likelihood of complete abstinence from cocaine
• A lower risk of relapse through 180 days after treatment

One of the most striking findings was the reduction in cocaine lapse risk over time. Participants who received psilocybin were far less likely to return to cocaine use during the six-month follow-up period. Researchers also reported that no serious adverse events occurred during the trial.

While the study was relatively small, the findings are being viewed as highly promising because cocaine addiction has historically been difficult to treat.

How Could Psilocybin Help Addiction?

Scientists are still trying to fully understand why psilocybin appears to help some people struggling with addiction, but several theories are emerging.

One possibility is that psilocybin temporarily disrupts deeply ingrained patterns of compulsive behavior and negative thinking. Addiction often becomes a repetitive cycle driven by habit, trauma, stress, and reward-seeking behavior. Psychedelic-assisted therapy may help people view those patterns differently.

Some participants in psychedelic studies describe experiencing:

• Increased emotional openness
• Greater self-awareness
• A renewed sense of meaning or purpose
• Reduced feelings of hopelessness
• Improved connection with others

Researchers also believe psilocybin may help increase psychological flexibility, allowing individuals to break away from destructive behavioral loops. Additionally, brain imaging studies from other psychedelic research suggest psilocybin may temporarily alter communication between brain regions involved in self-perception, emotion, and reward processing.

The Role of Therapy Matters

One of the most important takeaways from this research is that psilocybin was not used casually or recreationally. Participants received extensive psychological support throughout the study.

The treatment model included:

• Screening and preparation
• Professional supervision during dosing
• Integration therapy afterward
• Cognitive behavioral treatment techniques

This distinction is critical because researchers caution that psychedelic therapy is very different from unsupervised psychedelic use. Clinical environments are carefully designed to reduce risks and maximize therapeutic benefits. Experts also stress that psychedelics are not a “magic cure” for addiction. Recovery remains complex and often requires long-term support, lifestyle changes, and ongoing care.

The Future of Addiction Treatment

The findings add to a growing shift in how researchers think about addiction treatment. For years, much of addiction medicine focused primarily on symptom suppression or behavioral control. Psychedelic-assisted therapy may represent a different model, one centered on emotional processing, personal insight, and long-term psychological change.

The study’s authors concluded that psilocybin appeared safe and effective for treating cocaine use disorder in vulnerable and underrepresented populations, though they emphasized that larger studies are still needed.

Future research will likely explore:

• Larger and more diverse participant groups
• Long-term outcomes beyond six months
• Optimal dosing strategies
• How psilocybin compares to existing therapies
• Whether multiple sessions improve results

Researchers will also continue examining how psychedelic-assisted therapy could potentially help with other substance use disorders, including alcohol, nicotine, and methamphetamine dependence.

The Parallel Path: Lessons from Cannabis

The journey of psilocybin-assisted therapy into mainstream medicine echoes the evolving perception of cannabis. For decades, both substances were largely viewed through a lens of stigma and prohibition. However, just as modern research has increasingly highlighted the potential of medical cannabis to serve as a harm-reduction tool—specifically in helping patients reduce or discontinue high-risk opioid use for chronic pain—psychedelic science is now prompting a similar reconsideration.

Much like the shift seen with cannabis, where the focus has moved from purely recreational concerns to legitimate therapeutic applications, the conversation around psilocybin is emphasizing that “unexpected places” can yield profound medical (PROF ) breakthroughs. Both fields highlight a growing interest in leveraging natural compounds to treat complex conditions that have long resisted conventional pharmaceutical approaches. By observing how cannabis has been successfully integrated into pain management and harm-reduction strategies, researchers are better equipped to navigate the regulatory and social hurdles that lie ahead for psychedelic-assisted therapy.

A Promising but Early Area of Research

Although the results are encouraging, psilocybin therapy for cocaine addiction is still experimental and not currently approved as a standard medical treatment. Larger clinical trials will be necessary before regulators determine whether it can eventually become part of mainstream addiction care.

Still, the research represents an important development in a field that has struggled for decades to find effective treatment options for cocaine use disorder. For many experts, the study signals a broader shift toward exploring innovative therapies that address not only addiction itself but also the underlying emotional and psychological factors driving it.

As psychedelic science continues evolving, studies like this may help reshape the future of addiction treatment and open the door to entirely new approaches for recovery.

References:

^{1. Hendricks PS, Lappan SN, Shelton RC, et al. Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(5):e2611029. doi:10.1001/jamanetworkopen.2026.11029 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848757#250995011}